Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jan;67(1):190–197. doi: 10.1038/bjc.1993.33

Dose intensity analysis in advanced ovarian cancer patients.

V Torri 1, E L Korn 1, R Simon 1
PMCID: PMC1968241  PMID: 8427779

Abstract

To determine if chemotherapy dose intensity influences treatment outcome in advanced ovarian cancer, all randomised studies of first line chemotherapy, published between 1975 and 1989, were analysed for relationships between planned dose intensity and (a) objective response and (b) median survival. Total dose intensity of each study regimen was calculated and a weighted regression model providing for systemic differences in response or survival among studies was utilised. Hence, treatment arms of different studies were never directly compared. In addition, relative dose intensities of individual drugs within combinations was similarly evaluated. The improvement in objective response rate when adding one unit of total dose intensity ranged between 12% and 16% depending on baseline response rate. The improvement in median survival when adding one unit of total dose intensity ranged between 2 and 4 months. One unit of total dose intensity corresponds to, for example, 20 mg m2 week of cisplatin, or 25 mg m2 week of doxorubicin, or 350 mg m2 week of cyclophosphamide. The analysis of individual drugs suggested that doxorubicin and the platinum compounds were about equally effective, with cyclophosphamide being less effective. The methodological benefits and limitations of the approach used and the implication of the results are discussed.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aabo K., Hald I., Hørbov S., Dombernowsky P., Hansen H. H., Sørensen H. M., Lundvall F., Nielsen N. C., Sørensen B. L. A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. Eur J Cancer Clin Oncol. 1985 Apr;21(4):475–481. doi: 10.1016/0277-5379(85)90040-9. [DOI] [PubMed] [Google Scholar]
  2. Adams M., Johansen K. A., James K. W., Rocker I. A controlled clinical trial in advanced ovarian cancer. Clin Radiol. 1982 Mar;33(2):161–163. doi: 10.1016/s0009-9260(82)80049-4. [DOI] [PubMed] [Google Scholar]
  3. Adams M., Kerby I. J., Rocker I., Evans A., Johansen K., Franks C. R. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol. 1989;28(1):57–60. doi: 10.3109/02841868909111182. [DOI] [PubMed] [Google Scholar]
  4. Alberts D. S., Mason-Liddil N., O'Toole R. V., Abbott T. M., Kronmal R., Hilgers R. D., Surwit E. A., Eyre H. J., Baker L. H. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study. Gynecol Oncol. 1989 Jan;32(1):8–15. doi: 10.1016/0090-8258(89)90841-x. [DOI] [PubMed] [Google Scholar]
  5. Barker G. H., Wiltshaw E. Randomised trial comparing low-dose cisplatin and chlorambucil with low-dose cisplatin, chlorambucil, and doxorubicin in advanced ovarian carcinoma. Lancet. 1981 Apr 4;1(8223):747–750. doi: 10.1016/s0140-6736(81)92625-8. [DOI] [PubMed] [Google Scholar]
  6. Barlow J. J., Lele S. B. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma. Cancer Treat Rep. 1984 Dec;68(12):1433–1438. [PubMed] [Google Scholar]
  7. Barlow J. J., Piver M. S., Lele S. B. High-dose methotrexate with "RESCUE" plus cyclophosphamide as initial chemotherapy in ovarian adenocarcinoma. A randomized trial with observations on the influence of C parvum immunotherapy. Cancer. 1980 Sep 15;46(6):1333–1338. doi: 10.1002/1097-0142(19800915)46:6<1333::aid-cncr2820460606>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  8. Barlow J. J., Piver M. S. Single agent vs combination chemotherapy in the treatment of ovarian cancer. Obstet Gynecol. 1977 May;49(5):609–611. [PubMed] [Google Scholar]
  9. Begg C. B., Berlin J. A. Publication bias and dissemination of clinical research. J Natl Cancer Inst. 1989 Jan 18;81(2):107–115. doi: 10.1093/jnci/81.2.107. [DOI] [PubMed] [Google Scholar]
  10. Bell D. R., Woods R. L., Levi J. A., Fox R. M., Tattersall M. H. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. Aust N Z J Med. 1982 Jun;12(3):245–249. doi: 10.1111/j.1445-5994.1982.tb02469.x. [DOI] [PubMed] [Google Scholar]
  11. Bertelsen K., Jakobsen A., Andersen J. E., Ahrons S., Pedersen P. H., Kiaer H., Arffmann E., Bichel P., Boestofte E., Strøyer I. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol. 1987 Oct;28(2):161–169. doi: 10.1016/0090-8258(87)90210-1. [DOI] [PubMed] [Google Scholar]
  12. Bezwoda W. R. Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide. Med Pediatr Oncol. 1986;14(1):26–29. doi: 10.1002/mpo.2950140107. [DOI] [PubMed] [Google Scholar]
  13. Bolis G., Bortolozzi G., Carinelli G., D'Incalci M., Gramellini F., Morasca L., Mangioni C. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study. Cancer Chemother Pharmacol. 1980;4(2):129–132. doi: 10.1007/BF00254034. [DOI] [PubMed] [Google Scholar]
  14. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  15. Bruckner H. W., Cohen C. J., Goldberg J. D., Kabakow B., Wallach R. C., Deppe G., Greenspan E. M., Gusberg S. B., Holland J. F. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin. Cancer. 1981 May 1;47(9):2288–2294. doi: 10.1002/1097-0142(19810501)47:9<2288::aid-cncr2820470931>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  16. Bruckner H. W., Dinse G. E., Davis T. E., Falkson G., Creech R. H., Arseneau J. C., Greenspan E. M., Brodovsky H. S., Pagano M., Hahn R. G. A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer. Cancer. 1985 Jan 1;55(1):26–40. doi: 10.1002/1097-0142(19850101)55:1<26::aid-cncr2820550105>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  17. Carmo-Pereira J., Costa F. O., Henriques E., Ricardo J. A. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). Cancer. 1981 Nov 1;48(9):1947–1951. doi: 10.1002/1097-0142(19811101)48:9<1947::aid-cncr2820480906>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  18. Carmo-Pereira J., Costa F. O., Henriques E. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1983;10(2):100–103. doi: 10.1007/BF00446218. [DOI] [PubMed] [Google Scholar]
  19. Conte P. F., Bruzzone M., Chiara S., Sertoli M. R., Daga M. G., Rubagotti A., Conio A., Ruvolo M., Rosso R., Santi L. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol. 1986 Jun;4(6):965–971. doi: 10.1200/JCO.1986.4.6.965. [DOI] [PubMed] [Google Scholar]
  20. De Palo G. M., De Lena M., Bonadonna G. Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treat Rep. 1977 May-Jun;61(3):355–357. [PubMed] [Google Scholar]
  21. DeVita V. T. Dose-response is alive and well. J Clin Oncol. 1986 Aug;4(8):1157–1159. doi: 10.1200/JCO.1986.4.8.1157. [DOI] [PubMed] [Google Scholar]
  22. Decker D. G., Fleming T. R., Malkasian G. D., Jr, Webb M. J., Jeffries J. A., Edmonson J. H. Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol. 1982 Oct;60(4):481–487. [PubMed] [Google Scholar]
  23. Delgado G., Smith F. P., McLaughlin E. K., Tuholski N. Single agent vs. combination chemotherapy for ovarian cancer. Am J Clin Oncol. 1985 Feb;8(1):33–37. doi: 10.1097/00000421-198502000-00042. [DOI] [PubMed] [Google Scholar]
  24. Edmonson J. H., Fleming T. R., Decker D. G., Malkasian G. D., Jorgensen E. O., Jefferies J. A., Webb M. J., Kvols L. K. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep. 1979 Feb;63(2):241–247. [PubMed] [Google Scholar]
  25. Edmonson J. H., McCormack G. W., Fleming T. R., Cullinan S. A., Krook J. E., Malkasian G. D., Podratz K. C., Mailliard J. A., Jefferies J. A., Barlow J. F. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas. Cancer Treat Rep. 1985 Nov;69(11):1243–1248. [PubMed] [Google Scholar]
  26. Edwards C. L., Herson J., Gershenson D. M., Copeland L. J., Wharton J. T. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer. Gynecol Oncol. 1983 Apr;15(2):261–277. doi: 10.1016/0090-8258(83)90082-3. [DOI] [PubMed] [Google Scholar]
  27. Geller N. L., Hakes T. B., Petroni G. R., Currie V., Kaufman R. Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer. 1990 Oct 15;66(8):1678–1684. doi: 10.1002/1097-0142(19901015)66:8<1678::aid-cncr2820660804>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  28. Gelman R. S. Keeping an open mind about the doses of chemotherapy. J Natl Cancer Inst. 1990 Sep 19;82(18):1446–1447. doi: 10.1093/jnci/82.18.1446. [DOI] [PubMed] [Google Scholar]
  29. Gelman R., Neuberg D. Making cocktails versus making soup. J Clin Oncol. 1991 Feb;9(2):200–203. doi: 10.1200/JCO.1991.9.2.200. [DOI] [PubMed] [Google Scholar]
  30. Green J. A., Dawson A. A., Fell L. F., Murray S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol. 1980 May;9(5):511–514. doi: 10.1111/j.1365-2125.1980.tb05847.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Grönroos M., Nieminen U., Kauppila A., Kauppila O., Saksela E., Väyrynen M. A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation. Eur J Obstet Gynecol Reprod Biol. 1984 Apr;17(1):33–42. doi: 10.1016/0028-2243(84)90078-9. [DOI] [PubMed] [Google Scholar]
  32. Henderson I. C., Hayes D. F., Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988 Sep;6(9):1501–1515. doi: 10.1200/JCO.1988.6.9.1501. [DOI] [PubMed] [Google Scholar]
  33. Hernádi Z., Juhász B., Póka R., Lampé L. G. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer. Int J Gynaecol Obstet. 1988 Oct;27(2):199–204. doi: 10.1016/0020-7292(88)90008-2. [DOI] [PubMed] [Google Scholar]
  34. Johnsson J. E., Tropé C., Mattsson W., Grundsell H., Aspegren K., Könyves I. Phase II study of Leo 1031 (prednimustine) in advanced ovarian carcinoma. Cancer Treat Rep. 1979 Mar;63(3):421–424. [PubMed] [Google Scholar]
  35. Klasa R. J., Murray N., Coldman A. J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991 Mar;9(3):499–508. doi: 10.1200/JCO.1991.9.3.499. [DOI] [PubMed] [Google Scholar]
  36. L'Abbé K. A., Detsky A. S., O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987 Aug;107(2):224–233. doi: 10.7326/0003-4819-107-2-224. [DOI] [PubMed] [Google Scholar]
  37. Lambert H. E., Berry R. J. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J (Clin Res Ed) 1985 Mar 23;290(6472):889–893. doi: 10.1136/bmj.290.6472.889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Leonard R. C., Smart G. E., Livingstone J. R., Cornbleet M. A., Kerr G. R., Fletcher S., Webb J. N., Smyth J. F. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1989;23(2):105–110. doi: 10.1007/BF00273526. [DOI] [PubMed] [Google Scholar]
  39. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  40. Levin L., Hryniuk W. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin Oncol. 1987 Dec;14(4 Suppl 4):12–19. [PubMed] [Google Scholar]
  41. Mangioni C., Bolis G., Pecorelli S., Bragman K., Epis A., Favalli G., Gambino A., Landoni F., Presti M., Torri W. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464–1471. doi: 10.1093/jnci/81.19.1464. [DOI] [PubMed] [Google Scholar]
  42. Mangioni C., Bolis G., Pecorelli S., Bragman K., Epis A., Favalli G., Gambino A., Landoni F., Presti M., Torri W. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464–1471. doi: 10.1093/jnci/81.19.1464. [DOI] [PubMed] [Google Scholar]
  43. Meyer R. M., Hryniuk W. M., Goodyear M. D. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol. 1991 Feb;9(2):339–347. doi: 10.1200/JCO.1991.9.2.339. [DOI] [PubMed] [Google Scholar]
  44. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Vriesendorp R., Kooyman C. D., van Lindert A. C., Hamerlynck J. V., van Lent M., van Houwelingen J. C. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet. 1984 Sep 15;2(8403):594–600. doi: 10.1016/s0140-6736(84)90594-4. [DOI] [PubMed] [Google Scholar]
  45. Neijt J. P., ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Willemse P. H., Heintz A. P., van Lent M., Trimbos J. B., Bouma J., Vermorken J. B. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol. 1987 Aug;5(8):1157–1168. doi: 10.1200/JCO.1987.5.8.1157. [DOI] [PubMed] [Google Scholar]
  46. Omura G. A., Bundy B. N., Berek J. S., Curry S., Delgado G., Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1989 Apr;7(4):457–465. doi: 10.1200/JCO.1989.7.4.457. [DOI] [PubMed] [Google Scholar]
  47. Omura G. A., Morrow C. P., Blessing J. A., Miller A., Buchsbaum H. J., Homesley H. D., Leone L. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983 Mar 1;51(5):783–789. doi: 10.1002/1097-0142(19830301)51:5<783::aid-cncr2820510506>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  48. Omura G., Blessing J. A., Ehrlich C. E., Miller A., Yordan E., Creasman W. T., Homesley H. D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 1;57(9):1725–1730. doi: 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  49. Richardson G. S., Scully R. E., Nikrui N., Nelson J. H., Jr Common epithelial cancer of the ovary (2). N Engl J Med. 1985 Feb 14;312(7):415–424. doi: 10.1056/NEJM198502143120706. [DOI] [PubMed] [Google Scholar]
  50. Schwartz P. E., Chambers J. T., Kohorn E. I., Chambers S. K., Weitzman H., Voynick I. M., MacLusky N., Naftolin F. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial. Cancer. 1989 Mar 15;63(6):1074–1078. doi: 10.1002/1097-0142(19890315)63:6<1074::aid-cncr2820630606>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  51. Schwartz P. E., Lawrence R., Katz M. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):137–141. [PubMed] [Google Scholar]
  52. Sessa C., Bolis G., Colombo N., D'Incalci M., Mermillod B., Valente I., Mangioni C. Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial. Cancer Chemother Pharmacol. 1985;14(3):222–228. doi: 10.1007/BF00258120. [DOI] [PubMed] [Google Scholar]
  53. Tomirotti M., Perrone S., Giè P., Canaletti R., Carpi A., Biasoli R., Lombardi F., Giovanninetti A., Mensi F., Villa S. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial. Tumori. 1988 Oct 31;74(5):573–577. doi: 10.1177/030089168807400514. [DOI] [PubMed] [Google Scholar]
  54. Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol. 1987 Oct;70(4):582–586. [PubMed] [Google Scholar]
  55. Wilbur D. W., Rentschler R. E., Wagner R. J., Keeney E. D., King A., Hilliard D. A. Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. J Surg Oncol. 1987 Mar;34(3):165–169. doi: 10.1002/jso.2930340306. [DOI] [PubMed] [Google Scholar]
  56. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]
  57. Wiltshaw E., Evans B., Rustin G., Gilbey E., Baker J., Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol. 1986 May;4(5):722–729. doi: 10.1200/JCO.1986.4.5.722. [DOI] [PubMed] [Google Scholar]
  58. Young R. C., Chabner B. A., Hubbard S. P., Fisher R. I., Bender R. A., Anderson T., Simon R. M., Canellos G. P., DeVita V. T., Jr Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7;299(23):1261–1266. doi: 10.1056/NEJM197812072992301. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES